|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SSH2 |
Gene summary for SSH2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SSH2 | Gene ID | 85464 |
| Gene name | slingshot protein phosphatase 2 | |
| Gene Alias | SSH-2 | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | B4DK64 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85464 | SSH2 | CCI_1 | Human | Cervix | CC | 8.18e-19 | 1.35e+00 | 0.528 |
| 85464 | SSH2 | CCI_2 | Human | Cervix | CC | 2.65e-03 | 5.11e-01 | 0.5249 |
| 85464 | SSH2 | CCI_3 | Human | Cervix | CC | 1.26e-22 | 1.11e+00 | 0.516 |
| 85464 | SSH2 | CCII_1 | Human | Cervix | CC | 1.79e-08 | 4.03e-01 | 0.3249 |
| 85464 | SSH2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 5.09e-07 | -4.88e-01 | 0.0155 |
| 85464 | SSH2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.84e-02 | 3.57e-01 | -0.0811 |
| 85464 | SSH2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.83e-14 | 6.70e-01 | -0.1954 |
| 85464 | SSH2 | HTA11_411_2000001011 | Human | Colorectum | SER | 5.04e-12 | 8.38e-01 | -0.2602 |
| 85464 | SSH2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.33e-02 | -4.91e-01 | -0.0179 |
| 85464 | SSH2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.89e-03 | -4.11e-01 | 0.096 |
| 85464 | SSH2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.32e-22 | -6.65e-01 | 0.294 |
| 85464 | SSH2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.08e-03 | -3.41e-01 | 0.3005 |
| 85464 | SSH2 | A001-C-207 | Human | Colorectum | FAP | 1.17e-02 | -3.17e-01 | 0.1278 |
| 85464 | SSH2 | A015-C-203 | Human | Colorectum | FAP | 3.55e-33 | -5.84e-01 | -0.1294 |
| 85464 | SSH2 | A015-C-204 | Human | Colorectum | FAP | 1.76e-09 | -5.28e-01 | -0.0228 |
| 85464 | SSH2 | A014-C-040 | Human | Colorectum | FAP | 2.98e-05 | -5.21e-01 | -0.1184 |
| 85464 | SSH2 | A002-C-201 | Human | Colorectum | FAP | 1.12e-10 | -4.03e-01 | 0.0324 |
| 85464 | SSH2 | A001-C-119 | Human | Colorectum | FAP | 2.77e-08 | -5.72e-01 | -0.1557 |
| 85464 | SSH2 | A001-C-108 | Human | Colorectum | FAP | 3.73e-16 | -4.68e-01 | -0.0272 |
| 85464 | SSH2 | A002-C-205 | Human | Colorectum | FAP | 2.24e-32 | -6.98e-01 | -0.1236 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
| GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
| GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
| GO:003227110 | Cervix | CC | regulation of protein polymerization | 57/2311 | 233/18723 | 2.37e-07 | 1.03e-05 | 57 |
| GO:00081549 | Cervix | CC | actin polymerization or depolymerization | 51/2311 | 218/18723 | 4.05e-06 | 1.05e-04 | 51 |
| GO:00300419 | Cervix | CC | actin filament polymerization | 45/2311 | 191/18723 | 1.20e-05 | 2.54e-04 | 45 |
| GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
| GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
| GO:19029048 | Cervix | CC | negative regulation of supramolecular fiber organization | 40/2311 | 167/18723 | 2.39e-05 | 4.17e-04 | 40 |
| GO:00313339 | Cervix | CC | negative regulation of protein-containing complex assembly | 35/2311 | 141/18723 | 3.41e-05 | 5.55e-04 | 35 |
| GO:00308339 | Cervix | CC | regulation of actin filament polymerization | 40/2311 | 172/18723 | 4.90e-05 | 7.40e-04 | 40 |
| GO:00106399 | Cervix | CC | negative regulation of organelle organization | 68/2311 | 348/18723 | 7.40e-05 | 1.03e-03 | 68 |
| GO:00080649 | Cervix | CC | regulation of actin polymerization or depolymerization | 42/2311 | 188/18723 | 8.60e-05 | 1.15e-03 | 42 |
| GO:00308328 | Cervix | CC | regulation of actin filament length | 42/2311 | 189/18723 | 9.76e-05 | 1.27e-03 | 42 |
| GO:00514948 | Cervix | CC | negative regulation of cytoskeleton organization | 37/2311 | 163/18723 | 1.57e-04 | 1.88e-03 | 37 |
| GO:00163117 | Cervix | CC | dephosphorylation | 73/2311 | 417/18723 | 1.23e-03 | 9.87e-03 | 73 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
| hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
| hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
| hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
| hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
| hsa048102 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
| hsa048103 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
| hsa048104 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
| hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
| hsa048105 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
| hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
| hsa048106 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
| hsa043604 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
| hsa048107 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
| hsa043605 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
| hsa048108 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
| hsa043606 | Colorectum | CRC | Axon guidance | 43/1091 | 182/8465 | 4.38e-05 | 8.70e-04 | 5.90e-04 | 43 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SSH2 | SNV | Missense_Mutation | rs769551827 | c.3233N>T | p.Thr1078Ile | p.T1078I | protein_coding | deleterious_low_confidence(0) | benign(0.165) | TCGA-AA-3939-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SSH2 | SNV | Missense_Mutation | novel | c.162G>T | p.Glu54Asp | p.E54D | protein_coding | tolerated(0.13) | possibly_damaging(0.718) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SSH2 | SNV | Missense_Mutation | c.3224N>C | p.Lys1075Thr | p.K1075T | protein_coding | tolerated_low_confidence(0.19) | benign(0.009) | TCGA-AA-3956-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| SSH2 | SNV | Missense_Mutation | novel | c.3758N>G | p.His1253Arg | p.H1253R | protein_coding | tolerated_low_confidence(0.26) | benign(0.054) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SSH2 | SNV | Missense_Mutation | c.1153N>T | p.Arg385Trp | p.R385W | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| SSH2 | SNV | Missense_Mutation | c.3224N>C | p.Lys1075Thr | p.K1075T | protein_coding | tolerated_low_confidence(0.19) | benign(0.009) | TCGA-AA-A01C-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| SSH2 | SNV | Missense_Mutation | c.1590N>G | p.Ile530Met | p.I530M | protein_coding | tolerated_low_confidence(0.51) | benign(0.007) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| SSH2 | SNV | Missense_Mutation | novel | c.2267T>G | p.Ile756Ser | p.I756S | protein_coding | deleterious_low_confidence(0) | benign(0.369) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SSH2 | SNV | Missense_Mutation | novel | c.4049N>C | p.Phe1350Ser | p.F1350S | protein_coding | tolerated_low_confidence(0.16) | benign(0.015) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| SSH2 | SNV | Missense_Mutation | c.3172G>A | p.Ala1058Thr | p.A1058T | protein_coding | tolerated_low_confidence(0.29) | benign(0.003) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |